313 related articles for article (PubMed ID: 27049350)
21. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
Shen Y; Zeng L; Novosyadlyy R; Forest A; Zhu A; Korytko A; Zhang H; Eastman SW; Topper M; Hindi S; Covino N; Persaud K; Kang Y; Burtrum D; Surguladze D; Prewett M; Chintharlapalli S; Wroblewski VJ; Shen J; Balderes P; Zhu Z; Snavely M; Ludwig DL
MAbs; 2015; 7(5):931-45. PubMed ID: 26073904
[TBL] [Abstract][Full Text] [Related]
22. The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.
Zhang JF; Chen Y; Qiu XX; Tang WL; Zhang JD; Huang JH; Lin GS; Wang XF; Lin ZX
Tumour Biol; 2016 Mar; 37(3):3797-805. PubMed ID: 26472724
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function.
Williams CK; Li JL; Murga M; Harris AL; Tosato G
Blood; 2006 Feb; 107(3):931-9. PubMed ID: 16219802
[TBL] [Abstract][Full Text] [Related]
24. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
[TBL] [Abstract][Full Text] [Related]
25. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.
Thurston G; Noguera-Troise I; Yancopoulos GD
Nat Rev Cancer; 2007 May; 7(5):327-31. PubMed ID: 17457300
[TBL] [Abstract][Full Text] [Related]
26. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
[TBL] [Abstract][Full Text] [Related]
27. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
28. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
[TBL] [Abstract][Full Text] [Related]
29. Altered ratios of pro- and anti-angiogenic VEGF-A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma.
Ye X; Abou-Rayyah Y; Bischoff J; Ritchie A; Sebire NJ; Watts P; Churchill AJ; Bates DO
J Pathol; 2016 Jun; 239(2):139-51. PubMed ID: 26957058
[TBL] [Abstract][Full Text] [Related]
30. Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.
Sun HW; Wu C; Tan HY; Wang QS
Hepatogastroenterology; 2012 May; 59(115):924-9. PubMed ID: 22020917
[TBL] [Abstract][Full Text] [Related]
31. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
Harrington LS; Sainson RC; Williams CK; Taylor JM; Shi W; Li JL; Harris AL
Microvasc Res; 2008 Mar; 75(2):144-54. PubMed ID: 17692341
[TBL] [Abstract][Full Text] [Related]
32. Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth.
Ding XY; Ding J; Wu K; Wen W; Liu C; Yan HX; Chen C; Wang S; Tang H; Gao CK; Guo LN; Cao D; Li Z; Feng GS; Wang HY; Xu ZF
Oncogene; 2012 Jun; 31(23):2899-906. PubMed ID: 22002304
[TBL] [Abstract][Full Text] [Related]
33. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo.
Mashima T; Wakatsuki T; Kawata N; Jang MK; Nagamori A; Yoshida H; Nakamura K; Migita T; Seimiya H; Yamaguchi K
Sci Rep; 2021 Jul; 11(1):15125. PubMed ID: 34302038
[TBL] [Abstract][Full Text] [Related]
34. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
36. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
37. Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
Bessho H; Wong B; Huang D; Tan J; Ong CK; Iwamura M; Hart S; Dangl M; Thomas M; Teh BT
Cancer Invest; 2015; 33(8):378-86. PubMed ID: 26115098
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of δ-like ligand 4 and Notch1 in acute myeloid leukemia.
Zhang J; Ma D; Ye J; Zang S; Lu F; Yang M; Qu X; Sun X; Ji C
Oncol Rep; 2012 Oct; 28(4):1503-11. PubMed ID: 22858860
[TBL] [Abstract][Full Text] [Related]
40. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
